Skip to Main Content

Author Details

Tamara Jamaspishvili
Queen's University
2010
21
12
PMIDPaper TitleJournal TitlePublished Year
37037938A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.Br J Cancer2023
37126232Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.J Urol2023
37343766Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study.Mod Pathol2023
36010347A Computational Approach to Identification of Candidate Biomarkers in High-Dimensional Molecular Data.Diagnostics (Basel)2022
32884130High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts.Mod Pathol2021
34337530Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis.Eur Urol Open Sci2021
32129857Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN).J Natl Cancer Inst2020
32763409Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.J Mol Diagn2020
31160688Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies.Lab Invest2019
31530281Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.Cell Commun Signal2019
31433512A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.Prostate2019
30999388PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.Prostate2019
29460925Clinical implications of PTEN loss in prostate cancer.Nat Rev Urol2018
29776013Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy.Histopathology2018
27174589Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Mod Pathol2016
25983041A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Invest New Drugs2015
25939393A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.Prostate2015
24195515Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.Neoplasma2014
21520985Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients.Neoplasma2011
21788966Quadriplex model enhances urine-based detection of prostate cancer.Prostate Cancer Prostatic Dis2011
19652665Urine markers in monitoring for prostate cancer.Prostate Cancer Prostatic Dis2010
  • 1 - 21 of 21

Recommended Authors

GenomeDx Biosciences Inc.
Career Start Year 2012
Number of shared co-authors 10
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 6
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Career Start Year 2012
Number of shared co-authors 1
Erasmus Medical Center
Career Start Year 2011
Number of shared co-authors 1
Center for Genomic and Personalized Medicine, Guangxi Medical University
Career Start Year 2011
Number of shared co-authors 1
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 9
GenomeDx Biosciences Inc.
Career Start Year 2010
Number of shared co-authors 8
New York University Langone Health
Career Start Year 2010
Number of shared co-authors 2
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 7
Shanghai Changzheng Hospital
Career Start Year 2007
Number of shared co-authors 4
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 3
Veracyte Inc.
Career Start Year 2006
Number of shared co-authors 16
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2006
Number of shared co-authors 2
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 9
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 1
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 6
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 6
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 11
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 7
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 11
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 10
University College London
Career Start Year 1999
Number of shared co-authors 7
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 4
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 1
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 4
David Geffen School of Medicine at university of california los angeles
Career Start Year 1993
Number of shared co-authors 12
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 12
University of Bern
Career Start Year 1990
Number of shared co-authors 13
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 7
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 12

Collaborators

Queen's University
Co-authored papers 9
Queen's University
Co-authored papers 8
University of Sao Paulo
Co-authored papers 7
McGill University Health Centre, McGill University
Co-authored papers 5
Queen's University
Co-authored papers 5
University of British Columbia
Co-authored papers 4
McGill University and the Research Institute of the McGill University Health Centre
Co-authored papers 4
Research Institute of the McGill University Health Center (RI-MUHC)
Co-authored papers 4
University of Edinburgh
Co-authored papers 4
University of British Columbia
Co-authored papers 4
Current affiliation: IMV Inc.
Co-authored papers 3
CHRISTUS Santa Rosa Hospital-Medical Center
Co-authored papers 3
Fred Hutchinson Cancer Center
Co-authored papers 3
Co-authored papers 3
Queen's University Cancer Research Institute
Co-authored papers 3
University of Washington School of Medicine
Co-authored papers 3
Johns Hopkins University School of Medicine
Co-authored papers 3
McGill University Health Centre, McGill University
Co-authored papers 3
Eastern Virginia Medical School
Co-authored papers 3
McGill University Health Centre, McGill University
Co-authored papers 3
University of British Columbia
Co-authored papers 3
Schulich School of Medicine and Dentistry, University of Western Ontario
Co-authored papers 2
National Cancer Institute, National Institutes of Health
Co-authored papers 2
National Cancer Institute, National Institutes of Health
Co-authored papers 2
University of California los angeles
Co-authored papers 2
Washington State University Elson S. Floyd College of Medicine
Co-authored papers 2
University of Western Ontario
Co-authored papers 2
National Cancer Institute, National Institutes of Health
Co-authored papers 2
Ontario Institute for Cancer Research
Co-authored papers 2
Western University and London Regional Cancer Program
Co-authored papers 2